论文部分内容阅读
作者对９３例用￣１５３Ｓｍ－ＥＤＴＭＰ（乙二胺四甲撑膦酸）治疗的骨癌或骨转移癌患者的外周血常规、血清生化值作了分析。结果表明：用药后１周或１月，其血色素、白细胞、淋巳细胞、肝肾功能、电解质和酶学结果与治疗前的基础值比较，无显著性差异（Ｐ＞０．０５）；１月时血小板计数有减少（Ｐ＜０．０５）；１周时粒细胞计数降低，１月时与基础值对比，也无显著性差异（Ｐ＞０．０５）。使用”’Ｓｍ－ＥＤＴＭＰ剂量较大的患者（７４～１８５ＭＢｑ／ｋｇ），３月或１８个月后骨髓活捡无急性或慢性受抑制征象，也未发现骨髓各成分有中毒现象。
The authors analyzed the peripheral blood routine and serum biochemical values of 93 patients with bone cancer or bone metastases treated with ̄153Sm-EDTMP (ethylene diamine tetramethylene phosphonic acid). The results showed that there was no significant difference in hemoglobin, leucocyte, dripping cells, liver and kidney function, electrolytes, and enzymology results between the first week and the first month after treatment (P>0.05); The platelet count decreased at month (P<0.05); the granulocyte count decreased at 1 week and there was no significant difference (P>0.05) from the baseline value at the first month. In patients with a large dose of “Sm-EDTMP” (74-185 MBq/kg), there were no signs of acute or chronic bone marrow delirium after 3 months or 18 months, and no evidence of poisoning of bone marrow components was found.